|
|
|
|
|
| Giugliani,Roberto; Federhen,Andressa; Muñoz Rojas,Maria Verônica; Vieira,Taiane; Artigalás,Osvaldo; Lapagesse Pinto,Louise; Azevedo,Ana Cecília; Acosta,Angelina; Bonfim,Carmen; Lourenço,Charles Marques; Chong Ae,Kim; Horovitz,Dafne; Bonfim,Denize; Norato,Denise; Marinho,Diane; Palhares,Durval; Santos,Emerson Santana; Ribeiro,Erlane; Valadares,Eugênia; Guarany,Fábio; Lucca,Gisele Rosone de; Pimentel,Helena; Souza,Isabel Neves de; Correa Neto,Jordão; Fraga,José Carlos; Goes,José Eduardo; Cabral,José Maria; Simionato,José; Llerena Jr.,Juan; Jardim,Laura; Giuliani,Liane; Silva,Luiz Carlos Santana da; Santos,Mara L.; Moreira,Maria Angela; Kerstenetzky,Marcelo; Ribeiro,Márcia; Ruas,Nicole; Barrios,Patricia; Aranda,Paulo; Honjo,Rachel; Boy,Raquel; Costa,Ronaldo; Souza,Carolina; Alcantara,Flavio F.; Avilla,Silvio Gilberto A.; Fagondes,Simone; Martins,Ana Maria. |
| Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. This metabolic block leads to the accumulation of GAG in various organs and tissues of the affected patients, resulting in a multisystemic clinical picture, sometimes including cognitive impairment. Until the beginning of the XXI century, treatment was mainly supportive. Bone marrow transplantation improved the natural course of the disease in some types of MPS, but the morbidity and mortality restricted its use to selected cases. The identification of the genes involved, the new molecular biology tools and the availability of animal models made it possible to develop specific enzyme... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Mucopolisaccharidoses; Hurler syndrome; Hunter syndrome; Maroteaux-Lamy syndrome; Enzyme replacement therapy; Treatment guidelines. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572010000400001 |
| |
|
|
| Giugliani,Roberto; Federhen,Andressa; Michelin-Tirelli,Kristiane; Riegel,Mariluce; Burin,Maira. |
| Abstract Lysosomal storage diseases (LSDs) comprise a heterogeneous group of more than 50 genetic conditions of inborn errors of metabolism (IEM) caused by a defect in lysosomal function. Although there are screening tests for some of these conditions, diagnosis usually depends on specific enzyme assays, which are only available in a few laboratories around the world. A pioneer facility for the diagnosis of IEM and LSDs was established in the South of Brazil in 1982 and has served as a reference service since then. Over the past 34 years, samples from 72,797 patients were referred for investigation of IEM, and 3,211 were confirmed as having an LSD (4.41%, or 1 in 22), with 3,099 of these patients originating from Brazil. The rate of diagnosis has increased... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Lysosomal storage diseases; Epidemiology; Reference center; Biochemical genetics; Brazil. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572017000100031 |
| |
|
|
|
